RESUMO
This study reports the catalytic deracemization of ketones bearing stereocenters in the α-position in a single reaction via deprotonation, followed by enantioselective protonation. The principle of microscopic reversibility, which has previously rendered this strategy elusive, is overcome by a photoredox deprotonation through single electron transfer and subsequent hydrogen atom transfer (HAT). Specifically, the irradiation of racemic pyridylketones in the presence of a single photocatalyst and a tertiary amine provides nonracemic carbonyl compounds with up to 97% enantiomeric excess. The photocatalyst harvests the visible light, induces the redox process, and is responsible for the asymmetric induction, while the amine serves as a single electron donor, HAT reagent, and proton source. This conceptually simple light-driven strategy of coupling a photoredox deprotonation with a stereocontrolled protonation, in conjunction with an enrichment process, serves as a blueprint for other deracemizations of ubiquitous carbonyl compounds.
RESUMO
The mechanism of the Ru(II)-catalyzed anti-Markovnikov formal hydroalkylation of 1,3-dienes and enynes by hydrazones has been elucidated using density functional theory (DFT) calculations. Our results indicate that the C-C bond formation proceeds through a highly polar outer-sphere transition state (TS) stabilized by the THF solvent, not the ordered inner-sphere TS as originally proposed. The regioselectivity for 1,2-anti-Markovnikov addition is primarily due to the formation of an extensively π-conjugated intermediate after the nucleophilic attack on the 1-position of the diene. The stability of this intermediate means that nucleophilic attack at the 1-position is able to utilize the outer-sphere pathway, while attacks on all other positions of the diene must proceed through more crowded and less-favorable inner-sphere TSs. We show that the electronics of substituents on the hydrazone and the diene have a significant impact on the C-C formation barrier, which rationalizes the limitations on the substrate scope. The preferred coordination sphere around Ru(II) and the rigidity of the reacting substrates lead to a sterically demanding TS geometry, which explains the sensitivity of the reaction to the ligand size.
RESUMO
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation testing is recommended in metastatic non-small cell lung cancer (NSCLC). The objective of this study was to assess changes in EGFR mutation testing patterns and tyrosine kinase inhibitor (TKI) use in US veterans with stage III-IV NSCLC between 2013 and 2017. PATIENTS AND METHODS: Retrospective study using linked data from Department of Veterans Affairs (VA) Cancer Registry System, Corporate Data Warehouse, commercial laboratories, and clinical notes. Generalized linear mixed models accounting for clustering by VA facility were used to determine factors associated with EGFR mutation testing. RESULTS: From 2013 to 2017, EGFR mutation testing increased from 29.5% to 38.4% among veterans with stage III-IV NSCLC and from 47.0% to 57.4% among veterans with stage IV non-squamous disease. Factors associated with increased odds of testing included being married, Medicare enrollment, and adenocarcinoma histology. Factors associated with decreased odds of testing included Medicaid eligibility, stage III disease, increasing age, being a current or former smoker, increasing Charlson-Deyo comorbidity score, and receiving cancer care in the South. Appropriate use of a TKI rose from 2013 to 2017 (17.2% to 74.1%). CONCLUSION: EGFR mutation testing rates increased to almost 60% in the stage IV non-squamous NSCLC population in 2017, with residual opportunity for further increase. Several sociodemographic characteristics, comorbidities, and geographic regions were associated with EGFR mutation testing suggestive of inequitable testing decisions. Appropriate use of TKI improved drastically from 2013 to 2017 demonstrating rapidly changing practice patterns through the adoption phase of new treatment options.